Erratum: Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis. (Journal of Clinical Pharmacology (2014) 54 (1180-1187) DOI:10.1002/jcph.317);Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis

Journal of Clinical Pharmacology

Volumn 54, Issue 10, 2014, Pages 1180-1187

  Zhao, Yanli ^a   Cudkowicz, Merit E ^b   Shefner, Jeremy M ^c   Krivickas, Lisa ^b   David, William S ^b   Vriesendorp, Francine ^c   Pestronk, Alan ^d   Caress, James B ^e   Katz, Jonathan ^f   Simpson, Ericka ^g   Rosenfeld, Jeffrey ^h   Pascuzzi, Robert ⁱ   Glass, Jonathan ^j   Rezania, Kourosh ^k   Harmatz, Jerold S ^a   Schoenfeld, David ^b   Greenblatt, David J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c State University of New York Upstate Medical University: College of Medicine   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^g HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ INDIANA UNIVERSITY   (United States)

^j EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF CHICAGO   (United States)

more..

Author keywords

amyotrophic lateral sclerosis; ceftriaxone; cerebrospinal fluid uptake; HPLC micromethod; plasma pharmacokinetics

Indexed keywords

CEFTRIAXONE; PLACEBO; ANTIINFECTIVE AGENT;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG UPTAKE; ELIMINATION HALF-LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VOLUME OF DISTRIBUTION; VOLUME OF DISTRIBUTION AT STEADY-STATE; CLINICAL TRIAL; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; TISSUE DISTRIBUTION;

AMYOTROPHIC LATERAL SCLEROSIS; ANTI-BACTERIAL AGENTS; CEFTRIAXONE; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; TISSUE DISTRIBUTION;

EID: 84961307527     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.412     Document Type: Erratum

References (33)

1. Wijesekera LC, Leigh PN,. Amyotrophic lateral sclerosis. Orphanet J Rare Dis. 2009; 4: 3.
2. Rothstein JD,. Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. Adv Neurol. 1995; 68: 7-20.
3. Berry JD, Shefner JM, Conwit R, et al. Design and initial results of a multi-phase randomized trial of cefriaxone in amyotropic lateral sclerosis. PLoS. One. 2013; 8: e61177.
4. Vincent AM, Backus C, Taubman AA, Feldman EL,. Identification of candidate drugs for the treatment of ALS. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005; 6: 29-36.
5. Vincent AM, Sakowski SA, Schuyler A, Feldman EL,. Strategic approaches to developing drug treatments for ALS. Drug Discov Today. 2008; 13: 67-72.
6. Rothstein JD, Patel S, Regan MR, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005; 433: 73-77.
7. Lipski J, Wan CK, Bai JZ, Pi R, Li D, Donnelly D,. Neuroprotective potential of ceftriaxone in in vitro models of stroke. Neuroscience. 2007; 146: 617-629.
8. Rothstein JD, Kuncl RW,. Neuroprotective strategies in a model of chronic glutamate-mediated motor neuron toxicity. J Neurochem. 1995; 65: 643-651.
9. Thöne-Reineke C, Neumann C, Namsolleck P, et al. The beta-lactam antibiotic, ceftriaxone, dramatically improves survival, increases glutamate uptake and induces neurotrophins in stroke. J Hypertens. 2008; 26: 2426-2435.
10. Nizzardo M, Nardini M, Ronchi D, et al. Beta-lactam antibiotic offers neuroprotection in a spinal muscular atrophy model by multiple mechanisms. Exp Neurol. 2011; 229: 214-225.
11. Traynor BJ, Bruijn L, Conwit R, et al. Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology. 2006; 67: 20-27.
12. Perry TR, Schentag JJ,. Clinical use of ceftriaxone: a pharmacokinetic-pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding. Clin Pharmacokinet. 2001; 40: 685-694.
13. Yuk JH, Nightingale CH, Quintiliani R,. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinet. 1989; 17: 223-235.
14. Joynt GM, Lipman J, Gomersall CD, Young RJ, Wong EL, Gin T,. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother. 2001; 47: 421-429.
15. Reed MD, Rekate HL, Aronoff SC, Myers CM, Blumer JL,. Single-dose plasma and cerebrospinal fluid pharmacokinetics of ceftriaxone in infants and children. Clin Pharm. 1983; 2: 558-563.
16. Garot D, Respaud R, Lanotte P, et al. Population pharmacokinetics of ceftriaxone in critically ill septic patients: a reappraisal. Br J Clin Pharmacol. 2011; 72: 758-767.
17. Nau R, Prange HW, Muth P, et al. Passage of cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges. Antimicrob Agents Chemother. 1993; 37: 1518-1524.
18. Lutsar I, McCracken GH, Jr., Friedland IR,. Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis. 1998; 27: 1117-1127.
19. Chadwick EG, Yogev R, Shulman ST, Weinfeld RE, Patel IH,. Single-dose ceftriaxone pharmacokinetics in pediatric patients with central nervous system infections. J Pediatr. 1983; 102: 134-137.
20. Cherubin CE, Eng RH, Norrby R, Modai J, Humbert G, Overturf G,. Penetration of newer cephalosporins into cerebrospinal fluid. Rev Infect Dis. 1989; 11: 526-548.
21. Chandrasekar PH, Rolston KV, Smith BR, LeFrock JL,. Diffusion of ceftriaxone into the cerebrospinal fluid of adults. J Antimicrob Chemother. 1984; 14: 427-430.
22. Spector R,. Ceftriaxone transport through the blood-brain barrier. J Infect Dis. 1987; 156: 209-211.
23. Latif R, Dajani AS,. Ceftriaxone diffusion into cerebrospinal fluid of children with meningitis. Antimicrob Agents Chemother. 1983; 23: 46-48.
24. Radouane A, Pehourcq F, Tramu G, Creppy EE, Bannwarth B,. Influence of lipophilicity on the diffusion of cephalosporins into the cerebrospinal fluid. Fundam Clin Pharmacol. 1996; 10: 309-313.
25. Lutsar I, Friedland IR,. Pharmacokinetics and pharmacodynamics of cephalosporins in cerebrospinal fluid. Clin Pharmacokinet. 2000; 39: 335-343.
26. Sullins AK, Abdel-Rahman SM,. Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. Paediatr Drugs. 15: 93-117.
27. Ogawa M, Suzuki H, Sawada Y, Hanano M, Sugiyama Y,. Kinetics of active efflux via choroid plexus of beta-lactam antibiotics from the CSF into the circulation. Am J Physiol. 1994; 266: R392-R399.
28. Bradley JS, Farhat C, Stamboulian D, Branchini OG, Debbag R, Compogiannis LS,. Ceftriaxone therapy of bacterial meningitis: cerebrospinal fluid concentrations and bactericidal activity after intramuscular injection in children treated with dexamethasone. Pediatr Infect Dis J. 1994; 13: 724-728.
29. Popick AC, Crouthamel WG, Bekersky I,. Plasma protein binding of ceftriaxone. Xenobiotica. 1987; 17: 1139-1145.
30. Stoeckel K, McNamara PJ, Brandt R, Plozza-Nottebrock H, Ziegler WH,. Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics. Clin Pharmacol Ther. 1981; 29: 650-657.
31. Bourget P, Fernandez H, Quinquis V, Delouis C,. Pharmacokinetics and protein binding of ceftriaxone during pregnancy. Antimicrob Agents Chemother. 1993; 37: 54-59.
32. Demotes-Mainard FM, Vincon GA, Jarry CH, Albin HC,. Micromethod for determination of ceftriaxone in plasma and urine by high-performance liquid chromatography. J Pharm Biomed Anal. 1988; 6: 407-413.
33. Morgan DJ, Raymond K,. The effect of duration of intravenous infusion on maximum and threshold blood concentrations for drugs exhibiting biexponential elimination kinetics. J Pharmacokinet Biopharm. 1982; 10: 93-107.